RT期刊文章SR电子T1与Fremanezumab改善响应随时间恢复从情景的慢性偏头痛的患者分类(p1.10 - 013)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p1.10补充92 - 013签证官是15 A1 Rashmi Halker辛格A1迈克尔Marmura A1约书亚·科恩A1保罗·p·杨A1 Rongh首页ua杨年2019 UL //www.ez-admanager.com/content/92/15_supplement/p1.10 - 013. -文摘AB目的:评估应答率使用不同的响应阈值作为衡量Fremanezumab功效的成人慢性偏头痛(CM)恢复情景偏头痛(EM)。背景:厘米是一个截然不同的障碍,临床资料和响应模式与EM。Fremanezumab,全人源化单克隆抗体(IgG2Δa)选择性目标降钙素相关基因肽(CGRP怎样),在美国被批准用于偏头痛的预防治疗。占fremanezumab-treated患者降级从CM EM.Design /方法:在这52周,多中心、随机、双盲、与这些相应平行的组织研究中,患者CM收到皮下fremanezumab月(每月225毫克;起始剂量675毫克)或季度(675毫克每3个月)。这事后分析评估病人的比例达到≥50%,≥75%,或每月平均减少100%头痛的日子至少中等严重程度或偏头痛天厘米患者恢复到一个EM分类,定义为在≥15头痛天基线和< 15头痛的日子在12月。结果:患者813厘米的基线,548年恢复从CM。在这些患者中,在6月,66.9%,38.4%,和14.4%的病人在季度组;和72.8%、42.0%和15.5%,每月集团达到≥50%,≥75%,和月平均减少100%的头痛天数至少中等严重程度,分别。在12月,响应率进一步上升至75.7%,45.6%,和21.7%的季度集团;和77.7%、49.5%和18.0%,月度集团,分别。也显示出了类似的模式migraine-day应答率。结论:在fremanezumab-treated患者恢复从CM EM,临床相关的响应率长期持续,和更大的改进与长时间观察治疗。披露:Halker博士已经收到个人赔偿咨询、担任科学顾问委员会说,WebMD / Medlink或其他活动,安进,爱力根。Halker博士已经收到了个人在一篇社论中补偿电流神经病学和神经科学报告的能力。首页 Dr. Marmura has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Eli Lilly and Company, Alder, Promius, and Supernus Pharmaceuticals. Dr. Marmura has received research support from Teva Pharmaceuticals, Eli Lilly and Company, Theranica. Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva Pharmaceuticals. Dr. Cohen has received research support from This study was funded by Teva Pharmaceuticals, Petach Tikva, Israel. Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals. Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.